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Abstract: Hypoactive sexual desire disorder (HSDD) is a persistent deficiency or absence of sexual
fantasies and desire resulting in significant distress or interpersonal difficulty. Women with this
disorder may display a lack of motivation for sexual activity, reduced responsiveness to erotic
cues, a loss of interest during sexual activity, and avoidance of situations that could lead to sexual
activity. The pathophysiology of HSDD is thought to be centered around inhibitory and excitatory
hormones, neurotransmitters, and specific brain anatomy. Due to the multifactorial nature of HSDD,
treatment can be complex and must attempt to target the biological and psychosocial aspects of the
disorder. Bremelanotide is a melanocortin receptor agonist and has been recently approved by the
FDA to treat HSDD. Bremelanotide is administered intranasally or as a subcutaneous injection. The
recommended dosage of bremelanotide is 1.75 mg injected subcutaneously in the abdomen or thigh
at least 45 min before sexual activity. Studies showed improvements in desire, arousal, and orgasm
scores when 1.75 mg of bremelanotide was administered before sexual activity compared to a placebo.
Bremelanotide is a promising way to treat HSDD.
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1. Introduction
Hypoactive sexual desire disorder (HSDD) is the most prevalent female sexual health
disorder [1]. HSDD is defined as persistent deficiency or absence of sexual fantasies
and desire, resulting in significant distress or interpersonal difficulty [2]. The criteria
based on the Diagnostic and Statistical manual are “persistently or recurrently deficient
(or absent) sexual fantasies and desire for sexual activity: that causes marked distress or
interpersonal difficulty” [3]. Women with this disorder may display a lack of motivation
for sexual activity, reduced responsiveness to erotic cues, a loss of interest during sexual
activity, and avoidance of situations that could lead to sexual activity. Women who suffer
from HSDD commonly have reduced self-confidence, self-worth, and impaired body
image [2]. Diagnosis of HSDD requires personal distress and a change in sexual desire
for a least three months [4,5]. Subtypes of HSDD include those that are due solely to
“psychological factors” and “combined factors.” The HSDD can be due to psychological
factors, substances, or medical conditions in the combined subtype. The overall prevalence
of HSDD ranges from 8–19% [1,6–8]. The prevalence of HSDD increases with age and
has a higher prevalence in postmenopausal women. The risk is the greatest in younger
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women in surgical menopause and is associated with a less active sex life and decreased
sexual and relationship satisfaction [1]. Women who are premenopausal and experience
hypoactive sexual desire have higher levels of distress than postmenopausal women and
are more likely to seek help [9]. Women with distressing low sexual desire have a poorer
health-related quality of life. Women suffering from this disorder have reported decreased
physical functioning, vitality, social functioning, general health, mental health, and a loss
of femininity [1,10].
Several factors have been proposed to explain the etiology of low sexual desire and
the accompanying distress. These factors include partners and life situation, ethnicity and
culture, menopause status, central nervous system activity, and hormonal influences [10].
Married women or women living with a spouse or partner were more likely to have distressing low sexual desire than single women [11]. The PRESIDE study revealed that Caucasian
women were more likely than Black women to have low sexual desire [10]. Additionally,
brain areas such as the cerebral cortex may play a role in women developing HSDD. When
presented with erotic cues, women with HSDD were shown to have weaker cerebral cortex
activation in the right hemisphere and less deactivation in the left hemisphere than women
who did not have HSDD [12]. Various drugs or conditions that decrease dopamine levels
alter brain serotonin at serotonin 2A receptors or increase opioids at mu receptors have also
been shown to reduce or inhibit sexual desire [13,14]. Treatment of HSDD includes both
psychosocial and biological therapies. Psychosocial therapies include cognitive behavioral
therapy, sensate focus therapy, and mindfulness-based cognitive therapy. The current biological therapies for HSDD include flibanserin, testosterone therapy, bupropion (off-label
treatment), and buspirone (off-label treatment) [2].
2. Hypoactive Sexual Desire
2.1. Risk Factors
HSDD often goes underdiagnosed and undertreated due to the private nature of the
condition, making it difficult for patients to discuss with physicians. Understanding and
identifying risk factors associated with HSDD may help medical providers initiate conversations with patients. Several factors have been associated with a potentially increased
risk of HSDD, including biological, psychosocial, and pharmacological influences. Some
commonly studied biological risk factors for HSDD include age, hormone level, and other
comorbidities [15–17]. In a study on sexual distress in US women, Shifren et al. noted
that although sexual dysfunction increases with age, actual personal distress about sexual
issues decreases with age. This study reported that sexual distress occurred in 12% of the
studied population and was more common in mid-aged (45–64 years) women (14.8%),
followed by younger women (10.8%) and older women (8.9%) [8]. Other studies of both
US and European women have shown that postmenopausal women and women who have
undergone oophorectomy (surgical menopause) have lower sexual desire and a higher risk
of developing HSDD than pre-menopausal women with younger surgical postmenopausal
women being at greatest risk [18]. This finding suggests that the decrease in estrogen and
androgens after either natural or surgical menopause plays a role in losing sexual desire
and developing HSDD [17,19]. However, other postmenopausal symptoms, such as vaginal
dryness, may also lead to low sexual desire, highlighting the importance of excluding other
possible causes when considering the diagnosis of HSDD [20]. Comorbidities that have
also been associated with HSDD include chronic medical conditions (diabetes, coronary
artery disease, etc.), urinary incontinence, multiple sclerosis, Parkinson’s disease, and head
injury [17]. Leiblum et al. reported that women with HSDD had significantly more general
health issues than women without HSDD [1].
Studies have also reported psychosocial risks related to HSDD, including depression,
relationship status, and culture. Depression can both lead to and be a result of HSDD,
which is why it is important to determine the onset of depressive symptoms in relation
to low sexual desire and personal distress [10]. A study by Whalin-Jacobsen et al. looked
at the association of androgen levels and psychosocial factors with HSDD and found
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that androgen levels were associated with low sexual desire but not with HSDD [21].
However, relationship length and depressive symptoms were positively associated with
HSDD, underlining the importance of using a biopsychosocial model to understand and
diagnose HSDD [12]. The prevalence of low sexual desire has been reported to be similar
among surgically postmenopausal women of European descent; however, HSDD was more
prevalent in France (22%) than in Germany (7%), which suggests that culture plays a role
in developing HSDD [15].
Finally, it is important to consider pharmacological risks eliciting HSDD symptoms.
Selective Serotonin Reuptake Inhibitors (SSRIs) cause an increase in serotonin, which is
considered an inhibitory signal of the sexual drive leading to a blunted sexual response
and distressing low sexual desire. Opioid consumption can also be a cause of hypoactive
sexual desire [22]. Opioids can inhibit ovarian sex hormones and adrenal androgen production, which was found in a study that looked at women who were chronically using
sustained-action opioids [22,23]. Opioids exert their effects on adrenal androgen production
through their inhibitory effects on the hypothalamo-pituitary-adrenal axis [23]. However,
pharmacologically induced HSDD does not fit the Diagnostic Statistical Manual IV (DSM-IV)
criteria of HSDD.
2.2. Pathophysiology
The pathophysiology of HSDD is thought to be centered around inhibitory and excitatory hormones, neurotransmitters, and specific brain anatomy [16,24,25]. Estrogen,
testosterone, progesterone, and dopamine positively affect sexual desire, whereas serotonin,
opioids, and prolactin negatively affect sexual desire. Studies on rats suggest that estrogen
and testosterone exert their excitatory effect on sexual response via increasing dopamine
release and synthesis, respectively [26,27]. Conversely, serotonin reduces dopamine’s
positive effect on sexual response, leading to its inhibitory effect [25].
There is support in animal studies that testosterone also has a role in sexual desire. A
study performed by Maseroli et al. looked at non-aromatized androgen dihydrotestoerone
(DHT) and sexual behavior in female rats. The rats who were primed with estrogen and
received DHT displayed significantly more appetitive behaviors compared to the negative
controls [28]. The authors concluded that the administration of DHT enhances sexual
behavior. This argues that testosterone does play a role in sexual desire, suggesting that it
may also play a role in hypoactive sexual desire.
Neuroimaging studies have shown that HSDD is related to a sexual desire brain
network (SDBN) involving different areas of the brain that are either excited or repressed
by sexual stimuli. These studies suggest that atrophy of excitatory areas and hyperactivity
in inhibitory areas may lead to an increased risk of HSDD [24]. This study also reports that
this SDBN upholds the top-down processing model of HSDD, suggesting that women with
HSDD focus their attention more on evaluating their response to sexual stimuli rather than
on allowing themselves to be stimulated.
3. Current Treatment
Since a variety of biological, psychological, and social factors cause HSDD, current
treatments follow a biopsychosocial approach when evaluating and treating patients affected by the disorder [17,29,30]. Literature sources agree that there are significant challenges in the treatment of HSDD due to the lack of structured treatment regimens and clear
clinical guidelines, so treatments may vary on an individualized basis. Recommended
treatments start with office-based counseling before progressing to psychotherapy and/or
pharmacotherapy [17]. Prior to discussing the available treatment options, it is important to
note that approved treatments are limited in women with HSDD who are postmenopausal.
In this section, the current treatment will be discussed.
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3.1. Office-Based Counseling
Initially, office-based counseling may help treat HSDD with basic education and recommended lifestyle changes to improve sexual desire [31]. Clinician reluctance to discuss
sexual health is a significant barrier for treating patients with HSDD. As a result, clinicians
must be proactive in identifying sexual concerns and determining the best available treatment options. One popular approach for office-based counseling is the PLISSIT model, an
approach used for the treatment of sexual disorders. The model incorporates permission to
discuss problems and emotions, limited information on basic sexual function education
and resources, specific suggestions to address problems with directives, and the need for
more intensive treatment [32].
3.2. Psychological
Subsequently, psychological intervention has been recommended as a next treatment
modality if office-based counseling is ineffective or severe psychiatric issues, such as trauma
or abuse, are revealed for individual cases. Studies have suggested a collection of separate
interventions for female sexual dysfunction include cognitive-behavioral therapy (CBT),
mindfulness meditation therapy (MMT), and exercises for couples. However, although
controlled trials support the use of CBT and MMT for the treatment of HSDD, the efficacy
of these interventions has not been supported by scientific and regulatory standards for
drug treatment trials. Specifically, trials testing the efficacy of psychological treatments lack
the scientific and regulatory standards necessary for significant results. Standards include
reproducibility of intervention, randomizations, adequate control, and/or outcomes of
clinical relevance [33]
3.3. Pharmacological
A variety of pharmacological treatments have been tested for HSDD through randomized controlled clinical trials. However, current treatment options approved by the FDA
are still limited for women with the disorder. Treatment options focus on the inhibitory and
excitatory pathways linked to the regulation of responses for sexual cues. There are ongoing
investigations for novel treatments against HSDD cover hormone therapies and centrally
acting drugs intended to regulate these neural pathways [31]. Studies have measured
efficacy using patient-reported outcomes of sexual desire [34,35].
3.4. Off-Label Treatments
Alternative pharmacological approaches have been studied using off-label medications. One of the most common treatments tested for HSDD has been testosterone.
Testosterone is the primary sex hormone associated with the regulation of sexual desire,
and low levels in postmenopausal women are associated with loss of libido and decreased
sexual activity [17]. HSDD has been hypothesized to occur due to low circulating androgen
levels arising from either post-menopause or surgical removal of the ovaries [36,37]. Currently, data support that testosterone treatment shows efficacy in women with low levels
and a decrease in sexual desire [38–43]. Likewise, combination therapy of estrogen and
methyltestosterone has been shown to be a viable treatment for HSDD. However, studies
evaluating testosterone treatment for HSDD have not evaluated long-term treatments nor
have they established detailed results on safety and tolerability [44]. Currently, treatments
incorporating testosterone with other medications such as sildenafil are being evaluated
for improved sexual functioning [45].
Another off-label treatment being tested for HSDD is bupropion. Bupropion, a
dopamine and serotonin reuptake inhibitor, shows a lower incidence of sexual dysfunction
in patients with major depressive disorder [46–50]. In studies evaluating women with
HSDD, bupropion had a significantly increased rate of release compared to placebo [51,52].
It is thought that the increased availability of dopamine is what helps to decrease the risk
of sexual dysfunction and could be the reason it may be helpful in treating HSDD.
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3.5. Approved Agents
Flibanserin (postsynaptic 5-hydroxytryptamine 1A agonist and 2A antagonist) was the
first agent approved by the FDA for the treatment of HSDD [53]. Flibanserin functions by
decreasing serotonin levels and increasing both dopamine and norepinephrine levels [13,54].
Flibanserin has a high affinity for 5-HT1A receptors in the hippocampus and the prefrontal
cortex [55]. It also has agonist activity at the 5-HT1A postsynaptic receptors, which has some
downstream effects in altering the levels of other monoamines, including dopamine [55].
Flibanserin also causes a net increase in norepinephrine concentrations in the prefrontal
cortex through the disinhibition of the locus coeruleus noradrenergic neurons [55]. These
neurotransmitters have been associated with excitatory and inhibitory responses to sexual
cues implicated in HSDD [13]. Clinical trials have demonstrated that subjects experienced
improved satisfying sexual events after taking flibanserin compared to that of the control
group [56–64]. Flibanserin was initially rejected for approval by the FDA in 2010 due to
concerns over efficacy and safety data [53,65]. The most common adverse events included
somnolence and dizziness, which researchers have explored with alcohol use [54,62].
Finally, Bremelanotide, which is the main focus of this paper, is a melanocortin receptor
agonist and has been recently approved by the FDA for the treatment of HSDD [10,66]
4. Bremelanotide
Bremelanotide is a melanocortin receptor agonist which non-selectively activates
melanocortin 1 receptor (MC1R), melanocortin 2 receptor (MC2R), melanocortin 3 receptor
(MC3R), melanocortin 4 receptor (MC4R), and melanocortin 5 receptor (MC5R) receptors.
Activation of MC4R receptors modifies brain pathways involved in sexual responses [67].
Stimulation of MC4R receptors can also cause a transient increase in blood pressure and
a decrease in heart rate [68]. Bremelanotide is contraindicated in individuals with uncontrolled hypertension or cardiovascular disease [69]. Activation of MC1R receptors may
contribute to the adverse effect of hyperpigmentation [67]. Bremelanotide is able to be
administered intranasally or as a subcutaneous injection. The subcutaneous route has 100%
bioavailability and is associated with fewer side effects [68]. The recommended dosage of
bremelanotide is 1.75 mg injected subcutaneously in the abdomen or thigh at least 45 min
prior to sexual activity. Individuals should take only one dose every 24 h. Individuals
should refrain from taking more than eight doses of bremelanotide per month.
4.1. Mechanism of Action
The mechanism of action of bremelanotide is better understood for treating male
sexual dysfunction compared to female sexual dysfunction. In males, bremelanotide
primarily acts on MC3R and MC4R to help treat erectile dysfunction. The stimulation of
the melanocortin receptors, in general, causes a local increase of nitric oxide in the penis
leading to vasodilation and penile erection [70,71]. In females who suffer from HSDD,
abnormal sexual responses are due to an imbalance of various neurotransmitters. Amongst
these neurotransmitters, dopamine, and melanocortin stimulate attention and desire while
norepinephrine and oxytocin stimulate sexual arousal [72]. In females, administration
of bremelanotide acts primarily on the presynaptic MC4R and stimulates the release of
dopamine to portions of the nucleus accumbens, medial preoptic area, verbal tegmental
area, arcuate nucleus, and the medial and basolateral amygdala [66]. These brain areas
are involved in regulating the motivational, arousal, and appetitive aspects of sexual
behavior [73].
4.2. Pharmacodynamics of Bremelanotide
Bremelanotide is a non-selective agonist of the melanocortin receptors but is thought to
mainly act as an MC3R and MC4R receptor agonist. It is important to note that agonism of
the melanocortin receptors may lead to increased melanin expression, which can lead to hyperpigmentation [74]. The main adverse effects of bremelanotide include transient increases
in systolic and diastolic blood pressure, nausea, headache, and hyperpigmentation [75].

Neurol. Int. 2022, 14

80

In a study addressing the pharmacodynamics of bremelanotide, researchers monitored
ambulatory blood pressures of premenopausal women who received the drug daily for
eight days. They found a mean increase of 1.9 mmHg (daily SBP) and 1.7 mmHg (daily
DBP). Elevated SBP and DBP measurements peaked at 2.8 mmHg 4–8 h after receiving a
dose of bremelanotide and at 2.7 mmHg 0–4 h after receiving a dose, respectively.
4.3. Pharmacokinetics of Bremelanotide
After subcutaneous administration of bremelanotide, its mean maximum plasma
concentration reaches 72.8 ng/mL, and AUC is 276 hr*ng/mL. Bremelanotide’s Cmax level
reaches its plateau after a 7.5 mg dose administration. It takes about 1 h for Bremelanotide
to reach its maximum plasma concentration and does have 100% bioavailability with a
subcutaneous injection. It is noted to be 21% protein-bound in the serum [74]. After a
subcutaneous dose of bremelanotide, its half-life is 2.5 h and has a mean clearance of
6.5 +/− 1.0 L/h. Bremelanotide is a 7 amino acid chain and its metabolism consists of
multiple hydrolysis reactions [74]. It is renally excreted (64.8%), with some fecal excretion
(22.8%). Renal and hepatic impairment causes an increase in bremelanotide’s AUC. Bremelanotide decreases gastric emptying and has been shown to decrease the rate and extent of
absorption of other orally administered drugs, particularly indomethacin and naltrexone.
If patients are taking these drugs, they should avoid taking bremelanotide [75].
5. Clinical Studies: Safety and Efficacy
Bremelanotide (PT-141) is a melanocortinergic agent, a group of synthetic analogs
with demonstrated efficacy in improving male and female sexual dysfunction [66]. Across
multiple controlled clinical trials, bremelanotide has been demonstrated to be a possible
treatment option for women with hypoactive sexual desire disorder (HSDD).
5.1. Early Studies
The earliest clinical study of bremelanotide took place in a 2006 randomized controlled
clinical trial that evaluated physiological and subjective measurements of sexual arousal
and desire in premenopausal women diagnosed with HSDD [76]. Eighteen women received
intranasal doses of bremelanotide or matching placebo on the first and second in-clinic visit.
In each session, women were shown a 20-min normal video followed by a 20-min sexually
explicit video. The perceived sexual response was evaluated through questionnaires and
vaginal vasocongestion, which was measured by vaginal photoplethysmography. When
administered bremelanotide compared to the placebo, women reported moderate or high
sexual desire (p = 0.0114). Women also reported more positive responses to feelings of
genital arousal (p = 0.0833) and more satisfaction with the level of sexual arousal when
attempting sexual intercourse in the following 24 h (p = 0.0256). The study reported no
adverse effects from bremelanotide administration.
5.2. Phase I
To evaluate the safety and tolerability of bremelanotide, a phase I randomized doubleblind study evaluated the administration of bremelanotide in conjunction with ethanol
for analysis of pharmacokinetic interactions [77]. Patients (n = 24, 12 male and 12 female)
were randomized to 1 of 6 treatment groups and received single doses of either 20 mg
intranasal bremelanotide or placebo on days 1, 4, and 7 over the course of 7 days. Doses
were administered with or without 0.6 g/kg ethanol. Adverse events were evaluated using
vital signs, self-rated sedation scores, nursing and medical observations, and spontaneous
reporting by participants. Blood and urine samples were collected for clinical safety
laboratory tests. A physical exam and resting 12-lead electrocardiogram were performed on
subjects at baseline and on the 7th study day. In total, the percentage of adverse events was
highest for subjects who received ethanol and bremelanotide (75%) compared to subjects
who received bremelanotide only (67%) or ethanol only (58%). The study concluded that
there were no significant increases in the incidence of adverse events. Small decreases

Neurol. Int. 2022, 14

81

in mean blood pressure were only observed for bremelanotide and ethanol and ethanol
alone. There were also no clinically significant changes in blood pressure and no noticeable
pharmacokinetic interactions with bremelanotide administration alongside ethanol.
5.3. Phase 2b
A double-blind controlled trial in 2016 evaluated the long-term efficacy/safety of
bremelanotide administered subcutaneously for premenopausal women with HSDD and/or
female sexual arousal disorder (FSAD) [78,79]. Subjects were at least 21 years old, had at
least two years of normal sexual function, a stable monogamous relationship for at least six
months, and no underlying medical conditions which affected sexual function. Subjects
were double-blind placebo groups with either 0.75, 1.25, 1.75 mg BMT, or placebo in a
1:1:1:1 ratio. The groups were stratified by diagnosis (FSAD, HSDD, or both). Initially, two
doses were administered one week apart in the clinic before 12 weeks of self-administered
doses at home. Subjects would self-administer treatment with subcutaneous injection
approximately 45 min prior to sexual activity. Subjects who provided data after four weeks
of double-blind treatment were a part of the mITT population (n = 327). Primary efficacy
endpoints measured the change in sexually satisfying events (SSEs) from baseline to end of
the study. Secondary endpoints measured the changes in sexual desire and scores. Desire
was scored using the Female Sexual Function Index (FSFI) assesses female sexual function
using a self-assessment of sexual feelings and responses on a five- or six-choice scale [34,80].
To assess drug safety, the study used physical examination, vital signs, 12-lead ECGs, and
clinical lab tests to evaluate subjects. Blood pressure (BP) was also monitored using 2 h
and 24-h ambulatory blood pressure monitoring (ABPM). Patients were excluded from the
study if they sustained elevated BP values (SBP ≥ 150–170 mmHg/DBP ≥ 95–105 mmHg)
or had a change in baseline (SBP ≥ 30 mmHg/DBP ≥ 15 mmHg) for two to four consecutive
readings. This measure was included in response to safety concerns associated with earlier
studies of intranasal bremelanotide treatment. Specifically, melanocortin receptor agonists,
such as bremelanotide, may cause increases in BP [68].
Overall, 1.25 mg and 1.75 mg bremelanotide were demonstrated to have the greatest
efficacy profile. Subjects treated with bremelanotide in the 1.25/1.75 mg groups showed statistically significant improvement in primary and secondary endpoint measures compared
to the placebo group. The mean change in number of SSEs was +0.7 (2.4) events/month for
bremelanotide compared with +0.2 (2.3) for placebo (p = 0.0180). For secondary endpoints,
the mean change in FSFI score was +3.6 (5.7) versus +1.9 (5.9; p = 0.0017) and the mean
change in FSDS-DAO score was −11.1 (12.0) versus −6.8 (13.6; p = 0.0014). One specific
distinction between the two dosage groups was that 1.75 mg subjects showed a statistically
significant increase in all FSDS-DAO and FSFI outcomes compared to the total score and
desire score for the 1.25/1.75 mg integrated group.
The controlled trial did report treatment-emergent adverse events (TEAEs). The most
common occurrences took place in the 1.25 and 1.75 mg groups. The TEAEs include nausea
(22–24%), flushing (14–17%), and headache (9–14%). Seventy patients in the bremelanotide
group and seven patients in the placebo group experienced injection-site reactions (irritation,
rash, urticaria, swelling, pruritus, warmth, erythema, hematoma, hemorrhage, induration,
nodule, or pain). Three bremelanotide subjects and one placebo subject reported serious
TEAEs but were associated with underlying medical conditions instead of bremelanotide
usage. 13 subjects withdrew from double-blind treatment due to associated TEAEs.
Overall, bremelanotide was fairly well tolerated. Of the patients who experienced
injection-site reactions, 94% experienced mild events. Out of the 296 bremelanotide users
and 98 placebo users, subjects in the bremelanotide group reported more frequent adverse
reactions than placebo users for nausea (22% vs. 3%), vomiting (4% vs. 0%), and flushing
(16% vs. 0%). Although BP recordings demonstrated a decline in mean BP (3–6 mmHg)
and heart rate (5%), ABPM changes were not considered statistically significant between
the bremelanotide and placebo groups.
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From the previous phase 2b study, a responder analysis was carried out to evaluate the
minimal clinically important difference (MCID) for patient-reported outcomes (PROs) [79].
Scores were selected from premenopausal women who were affected by HSDD or mixed
HSDD/FSAD. Responder analyses evaluated the change from baseline to end-of-study
for seven endpoints. Each PRO endpoint used 1–4 different types of responder analyses:
planned analysis based on expert estimates, post hoc analyses, receiver operating characteristic (ROC) curves, and cumulative distribution function. From the responder rates,
those at the 1.75 mg dose in the miTT population showed statistical significance compared
with the placebo (p ≤ 0.03) at both primary and secondary endpoints. As a result, 1.75 mg
bremelanotide was chosen by researchers for phase 3 clinical studies to further test efficacy
and safety.
5.4. RECONNECT
Two-phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trials
(RECONNECT) were conducted between 2015–2016 to evaluate the safety and efficacy
of bremelanotide treatment for premenopausal women with HSDD [78]. Premenopausal
women 18 years or older with a stable monogamous relationship were recruited for the
studies. HSDD diagnosis was determined using the Diagnostic Screening Guide for HSDD
by an investigator or licensed health care provider. Subject eligibility was based on a
diagnosis of HSDD for more than six months and evidence of normal sexual functioning
for at least two years. Women who were pregnant, nursing, diagnosed with other female
sexual dysfunction disorders, or currently being treated for any psychiatric disorders were
excluded. Based on the data from a previous phase 2b clinical trial, 1.75 mg bremelanotide
was selected for testing due to optimal efficacy and safety profiles.
Women randomized to the safety (n = 1247) and efficacy (n = 1202) groups received
either the treatment or placebo for 24 weeks. Safety evaluations were performed at screening, monthly, then at the end of the study. Components included a physical examination,
BP assessment, ECG, and clinical laboratory testing. Primary efficacy endpoints involved
a change in Female Sexual Function Index-desire domain (FSFI-D) and Female Sexual
Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score from baseline to end-of-study.
Secondary endpoints measured the change in satisfying sexual events within 16 h of receiving treatment or placebo and reported within 72 h. Because both studies were identical in
design, based on exclusion/inclusion criteria, and efficacy and safety assessments, results
collected from each study were integrated together in this review.
In these two phase 3 trials, it was demonstrated that bremelanotide showed clinical
significance in the increase in sexual desire and decrease in distress related to low sexual
desire compared with placebo for premenopausal women with HSDD. Both primary
endpoints were achieved in the phase 3 trials. Specifically, women who took bremelanotide
had a statistically significant increase in sexual desire for each independent study and
combined (study 301: 0.30, p < 0.001; study 302: 0.42, p < 0.001; integrated studies 0.35,
p < 0.001) while having a significant decrease in distress associated with low sexual desire
(study 301: −0.37, p < 0.001; study 302: −0.29, p = 0.005; integrated studies −0.33, p < 0.001).
The co-primary endpoints not only yielded statistically significant data between treatment
groups but also had a significant response rate for studies 301 and 302 (bremelanotide: 58.3
and 58.2%, placebo: 36.1% and 35.4%). Higher response rates for the bremelanotide group
signified that the subjects found more meaningful clinical changes when administered
the treatment.
In both studies from baseline to the end of the study, women who were taking bremelanotide had a statistically significant increase in sexual desire (study 301 0.30, p < 0.001,
study 302 0.42, p < 0.001, integrated studies 0.35, p < 0.001) and had a statistically significant reduction in distress related to low sexual desire (study 301 −0.37, p < 0.001, study
302 −0.29, p = 0.005, integrated studies −0.33, p < 0.001) compared with the placebo [81].
The secondary endpoint was the change from baseline to end-of-study in the number
of satisfying sexual events that occurred within 16 h of study drug doses and reported
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within 72 h of occurring [81]. The change between the baseline and end-of-study number of
satisfying sexual events reported did not reach statistical significance between the treatment
groups (study 301 bremelanotide 0.0, placebo −0.1 p = 0.764, study 302 bremelanotide 0.0,
placebo 0.0 p = 0.702, integrated studies bremelanotide 0.0, placebo −0.1 p = 0.630). The
authors performed a post hoc exploratory analysis that showed that the difference in the
percentages of sexual events that were considered satisfying sexual events (defined as the
number of satisfying sexual events per total number of sexual encounters) increased in
the bremelanotide group when compared to the placebo group. Across both studies, the
differences in the percentage increased greater than two-fold in the bremelanotide group
when compared to the placebo (25% vs. 9.8% p < 0.001) [81].
Subjects who received bremelanotide experienced more adverse side effects compared
to those who received the placebo (76.6% vs. 58.2%). In both studies, bremelanotide users
experienced more frequent nausea (40% vs 1.3%), flushing (20.3% vs 0.3%), and headache
(11.3% vs 1.9%) than the placebo group. The TEAEs related to bremelanotide were nausea,
flushing, and headache. As reflected in the original phase, 2b study, mean increases in
subject BP and HR were modest. Of the 40% of the patients taking bremelanotide, only
8.1% discontinued the medication during the study due to this TEAE [81]. There were no
clinically significant changes to the other safety measures evaluated.
Overall, the phase 3 trials have shown that Bremelanotide holds promise as a treatment
for HSDD in postmenopausal women. The drug has demonstrated a clinical efficacy profile
with minimal safety concerns, which ultimately led to FDA approval in 2019 [67]. The
TEAEs experienced were related to tolerability and not safety concerns. It is important to
note, however, that the high response rates of the RECONNECT trial could be attributed
to the placebo effect, and this was noted by the authors. Table 1 summarizes the studies
discussed in this section.
Table 1. Clinical Efficacy and Safety.
Author
(Year).

Groups Studied and Intervention

Results and Findings

Diamond LE
et al., 2006

Evaluated physiological and subjective measurements of
sexual arousal and desire in premenopausal women
diagnosed with HSDD (n = 18).
Intranasal doses of bremelanotide or matching placebo
on the first and second in-clinic visit. In each session,
women were shown a 20-min normal video followed by
a 20-min sexually explicit video.
Perceived sexual response evaluated using
questionnaires and vaginal vasocongestion (measured
by vaginal photoplethysmography).

When administered bremelanotide women reported
moderate or high sexual desire compared to placebo
(p = 0.0114).
Women reported more positive responses to feelings of
genital arousal (p = 0.0833), and more satisfaction with
level of sexual arousal when attempting sexual
intercourse in the following 24 h (p = 0.0256).
No adverse effects from BMT administration.

Phase I
Evaluated the safety, tolerability, and hemodynamic and
pharmacokinetic effects of bremelanotide (BMT) when
administered with ethanol.
24 participants (12 men; 12 women) enrolled in the
study; received BMT or placebo with or without ethanol
for 7 consecutive days. Participants received single
intranasal doses of 20 mg BMT or placebo on days 1, 4,
and 7, with or without oral ethanol (0.6 g/kg).

Doses of 20 mg intranasal BMT, with or without
0.6 g/kg ethanol, were considered safe and well
tolerated with.
No clinically significant pharmacokinetic interactions
found between ethanol and BMT (both overall and by
sex). No significant drug-related hypotensive or
orthostatic hypotensive effects were noted.
Unchanged frequency of treatment-emergent adverse
events (TEAEs), no participants discontinued the
study because of adverse events.
Physical examination, electrocardiography, and
laboratory tests disclosed no clinically significant
changes.

Clayton AH
et al., 2017
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Table 1. Cont.
Author
(Year).

Groups Studied and Intervention

Results and Findings

Clayton AH
et al., 2016

Phase 2b
Premenopausal nonpregnant women at least 21 years
old with FSAD, HSDD or a combination of these
disorders for at least the preceding 6 months.
Patients randomized to receive placebo or BMT 0.75,
1.25 or 1.75 mg self-administered subcutaneously over
12 weeks.
Double-blind treatment began with two
self-administered in-clinic study-drug doses spaced
approximately 1 week apart. Dosing at-home, as-desired
approximately 45 min prior to anticipated sexual activity.
Primary end point was change in satisfying sexual
events/month. Secondary end points included total
score changes on female sexual function index and
female sexual distress scale-desire/arousal/orgasm.

The primary efficacy end point was each patient’s
change, from baseline to end of study (EOS), in the
number of SSEs. The mean change in number of SSEs
from baseline to EOS was +0.7 (2.4) events/month for
BMT 1.25/1.75 mg pooled, compared with +0.2 (2.3)
for placebo (p = 0.0180)
Secondary end points included change from baseline
to EOS in total FSFI score, FSFI domain scores for
desire and arousal, total FSDS-DAO score and
individual FSDS-DAO item #14 (arousal) and #13
(desire) scores.
Mean change in FSFI total score was +3.6 (5.7) versus
+1.9 (5.9; p = 0.0017) and the mean change in
FSDS-DAO total score was −11.1 (12.0) versus −6.8
(13.6; p = 0.0014)

Kingsberg AS
et al., 2019

RECONNECT
Evaluated the safety and efficacy of bremelanotide
1.75 mg administered. For premenopausal women with
hypoactive sexual desire disorder.
Randomized 1:1 to 24 weeks of treatment with
bremelanotide or placebo.
Primary end point was change in FSFI-D and
FSDS-DAO. Secondary end point was the number of
satisfying sexual events.

Women who were taking bremelanotide had a
statistically significant increase in sexual desire (study
301 0.30, p < 0.001, study 302 0.42, p < 0.001, integrated
studies 0.35, p < 0.001).
Statistically significant reduction in distress related to
low sexual desire (study 301 −0.37, p < 0.001, study
302 −0.29, p = 0.005, integrated studies
−0.33, p < 0.001) compared with placebo.
Patients taking bremelanotide experienced more
nausea, flushing, and headache (10% or more in both
studies) compared with placebo.

6. Conclusions
Hypoactive sexual desire disorder is a multi-faceted disorder involving biological,
psychological, and pharmacological influences. The sensitivity of this disorder often makes
it difficult to identify and treat. Further complicating treatment is the complex intertwinement between the biological and psychosocial causes of HSDD. Psychosocial factors such
as relationship status, culture, and menopausal status have been shown to influence sexual
desire and activity in women [10]. Additionally, the activity of hormones such as dopamine,
testosterone, and progesterone have been shown to have positive effects on sexual desire,
while other hormones such as serotonin and prolactin have been shown to impair sexual
desire by inhibiting dopamine release [26,27]. Treatment of HSDD is focused on reducing
sexual distress and improving sexual desire. Treatment options for HSDD include both
psychosocial approaches and pharmacotherapy. Psychosocial treatments include cognitive
behavioral therapy, mindfulness-based therapy, and couple’s therapy. Pharmacotherapy
options include flibanserin, bupropion, ospemifene, testosterone, and bremelanotide [2].
Bremelanotide is the most recent FDA-approved treatment for HSDD. Bremelanotide is
a nonselective melanotropin receptor agonist which primarily acts on MC4R receptors to
modulate brain pathways involved in sexual responses [81]. Bremelanotide has shown
efficacy in improving sexual responses in women suffering from HSDD. In comparison
to a placebo group, women taking bremelanotide have reported increased sexual desire
and more positive responses to feelings of genital arousal. Additionally, women taking
bremelanotide reported increased satisfaction with arousal levels when attempting intercourse [76]. Bremelanotide should be used cautiously in patients with cardiovascular
disease as it can decrease heart rate and increase blood pressure [68]. The most common
side effects of bremelanotide are nausea, vomiting, and flushing [69]. Bremelanotide shows
a promising way to treat HSDD.
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